AE Wealth Management LLC Acquires 65,682 Shares of Pfizer Inc. $PFE

AE Wealth Management LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,238,460 shares of the biopharmaceutical company’s stock after purchasing an additional 65,682 shares during the period. AE Wealth Management LLC’s holdings in Pfizer were worth $31,556,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PFE. Archer Investment Corp boosted its position in shares of Pfizer by 37.0% during the third quarter. Archer Investment Corp now owns 67,672 shares of the biopharmaceutical company’s stock worth $1,724,000 after acquiring an additional 18,281 shares during the last quarter. Addison Capital Co purchased a new stake in Pfizer in the 3rd quarter worth $683,000. Activest Wealth Management boosted its holdings in shares of Pfizer by 20.9% during the 3rd quarter. Activest Wealth Management now owns 24,815 shares of the biopharmaceutical company’s stock valued at $632,000 after purchasing an additional 4,293 shares during the last quarter. Great Lakes Advisors LLC grew its position in shares of Pfizer by 48.0% during the third quarter. Great Lakes Advisors LLC now owns 42,758 shares of the biopharmaceutical company’s stock valued at $1,089,000 after purchasing an additional 13,865 shares in the last quarter. Finally, Fidelis Capital Partners LLC increased its holdings in shares of Pfizer by 18.7% in the third quarter. Fidelis Capital Partners LLC now owns 32,384 shares of the biopharmaceutical company’s stock worth $825,000 after purchasing an additional 5,101 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 2.3%

PFE stock opened at $25.89 on Thursday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The stock has a market capitalization of $147.17 billion, a price-to-earnings ratio of 15.05 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $25.45 and its two-hundred day simple moving average is $25.01.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 100.00%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on PFE (supportive near-term catalyst that helped shares earlier in the week). Why Is Pfizer Stock Rising Tuesday?
• Positive Sentiment: Some bullish analysts/investors remain confident in Pfizer’s longer-term outlook, arguing recent policy moves don’t change their favorable stance. Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
• Neutral Sentiment: Profile pieces and analyst roundups (CEO interview, market commentary) provide context but limited immediate price impact. Pfizer’s CEO on leading after a moonshot—and making deals with Trump
• Neutral Sentiment: Market write-ups note recent outperformance vs. the market on specific days, useful for sentiment tracking but not a structural change. Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
• Negative Sentiment: Zacks Research downgraded Pfizer from “hold” to “strong sell,” which can trigger selling pressure from momentum/quant strategies and affect sentiment. Zacks Downgrade Coverage
• Negative Sentiment: The U.S. Centers for Medicare & Medicaid Services named Pfizer drugs for the next round of Medicare price negotiations — a material policy risk that could pressure revenue for listed products if negotiated prices are reduced. US Medicare names drugs for next price talks
• Negative Sentiment: Earnings preview commentary warns Q4 results may decline versus expectations, raising the risk of a miss or muted guidance that could weigh on the stock. Earnings Preview: Q4 Earnings Expected to Decline
• Negative Sentiment: Competitive risk: early data from Aclaris shows a hair‑loss candidate outperforming Pfizer’s Litfulo in preclinical/early results, a potential headwind for that franchise. Aclaris hair-loss drug shows faster results
• Negative Sentiment: Broader concerns about leverage and underperformance versus peers (Merck, J&J) keep analysts cautious ahead of secular headwinds like waning COVID product demand and an upcoming patent cliff. Pfizer vs. Merck Stock And JNJ

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PFE. Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. UBS Group assumed coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. Finally, Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.06.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.